[1]Patent:EP1417967,2004,A1.Locationinpatent:Page/Pagecolumn53
[1]Patent:US2003/130213,2003,A1
[2]Patent:US2011/275817,2011,A1
[3]Patent:CN107641106,2018,A
[1]Patent:US2003/130213,2003,A1
[2]Patent:US2002/13316,2002,A1
[1]Patent:US2003/130213,2003,A1
Title: Favipiravir (T-705) inhibits in vitro norovirus replication.
Journal: Biochemical and biophysical research communications 20120810
Title: Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
Journal: Antiviral research 20120401
Title: [Anti-influenza virus agent].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20120401
Title: [New antiviral agents of influenza].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20120401
Title: A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon.
Journal: PLoS pathogens 20120401
Title: Viral hemorrhagic fevers: advancing the level of treatment.
Journal: BMC medicine 20120101
Title: Monoclonal antibodies targeting the synthetic peptide corresponding to the polybasic cleavage site on H5N1 influenza hemagglutinin.
Journal: Journal of biomedical science 20120101
Title: Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever.
Journal: PLoS neglected tropical diseases 20111001
Title: Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir.
Journal: Antiviral chemistry & chemotherapy 20110512
Title: Caffeoylquinic acids are major constituents with potent anti-influenza effects in brazilian green propolis water extract.
Journal: Evidence-based complementary and alternative medicine : eCAM 20110101
Title: Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patients.
Journal: Advances in virology 20110101
Title: Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice.
Journal: PLoS pathogens 20101001
Title: [Present and future in development of new anti-influenza drugs].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20100901
Title: Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses.
Journal: PLoS pathogens 20100801
Title: Combination chemotherapy for influenza.
Journal: Viruses 20100801
Title: Antiviral strategies for pandemic and seasonal influenza.
Journal: Viruses 20100801
Title: Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models.
Journal: Antiviral research 20100501
Title: A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes.
Journal: Viruses 20100501
Title: Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog.
Journal: PloS one 20100101
Title: Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.
Journal: PloS one 20100101
Title: Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells.
Journal: The Journal of antimicrobial chemotherapy 20091001
Title: T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.
Journal: Antiviral research 20090601
Title: Effect of T-705 treatment on western equine encephalitis in a mouse model.
Journal: Antiviral research 20090601
Title: Developing new antiviral agents for influenza treatment: what does the future hold?
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090101
Title: Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents.
Journal: Antiviral research 20081201
Title: Current and future antiviral therapy of severe seasonal and avian influenza.
Journal: Antiviral research 20080401
Title: Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.
Journal: PloS one 20080101
Title: In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
Journal: Antimicrobial agents and chemotherapy 20070901
Title: Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
Journal: Antimicrobial agents and chemotherapy 20070301
Title: Strategies of development of antiviral agents directed against influenza virus replication.
Journal: Current pharmaceutical design 20070101
Title: Mechanism of action of T-705 against influenza virus.
Journal: Antimicrobial agents and chemotherapy 20050301
Title: In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
Journal: Antiviral chemistry & chemotherapy 20030901
Title: In vitro and in vivo activities of anti-influenza virus compound T-705.
Journal: Antimicrobial agents and chemotherapy 20020401
Title: Protein and energy utilization by the insect, Argyrotaenia velutinana (Walker), fed diets containing graded levels of an amino acid mixture.
Journal: Comparative biochemistry and physiology. A, Comparative physiology 19751201
Title: Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54.
Title: Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80.
